Research programme: antigen processing-independent epitopes - Apitope Technology

Drug Profile

Research programme: antigen processing-independent epitopes - Apitope Technology

Alternative Names: API F-VIII; ATX-F8-117; ATX-GD-450; ATX-UV1; ATX-UV2; iATX Factor VIII

Latest Information Update: 30 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Apitope Technology
  • Class Peptide vaccines
  • Mechanism of Action Immunomodulators; Interleukin 10 stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Haemophilia A
  • Research Uveitis

Most Recent Events

  • 09 Jun 2015 ATX F8 117 receives Orphan Drug status for Haemophilia A in USA
  • 25 Nov 2014 Apitope Technology receives Orphan Drug status for ATX F8 117 for Haemophilia A in European Union
  • 24 Jun 2013 Early research in Uveitis in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top